Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Coherus Oncology, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and in Item 10(f)(1) of Regulation S-K, therefore this disclosure item is not applicable. 36 Table of Contents